New Delhi News

“Cytomegalovirus Infections Pipeline” has been added to DelveInsight

Cytomegalovirus Infections Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competitors, launch date along with product development activities.

“Cytomegalovirus (CMV) Infection Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Cytomegalovirus (CMV) Infection market

Download free sample copy here- https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-pipeline-insight

Cytomegalovirus Infections Overview

Infection with cytomegalovirus (CMV) is very common. CMV Infections is a type of herpesvirus (herpesvirus type 5). Blood tests show that 60–90% of adults have had a CMV Infections infection at some time.

Cytomegalovirus Infections Key Players

• Roche
• CSL Behring
• Clinigen Group plc
• Takeda/Shire Pharmaceuticals
• Helocyte
• AlloVir
• Merck
• ModernaTX
• Hookipa Biotech

Cytomegalovirus Infections Drugs

• Valcyte
• Foscavir
• CytoGam
• Maribavir (TAK-602)
• Triplex
• Viralym-M
• V160
• mRNA-1647
• HB-101

Cytomegalovirus Infections Symptoms

CMV Infections may cause symptoms soon after infection and can also remain dormant (inactive) in various tissues for life. Various stimuli can reactivate the dormant CMV Infections, resulting in virus growth which can sometimes cause disease. The lungs, gastrointestinal tract, brain, spinal cord, or eyes may be infected.

Cytomegalovirus Infections Emerging Therapy Assessment

The available therapeutics treatment options in CMV Infection Landscape aim to reduce the disease burden. The current market anticipates the emergence of emerging products namely V160 (Merck), mRNA-1647 (ModernaTX), HB-101/VaxWave (Hookipa Biotech), Triplex (Helocyte), Maribavir (TAK-602)(Takeda/Shire Pharmaceuticals), and Viralym-M (AlloVir).

All the upcoming therapies are either for prevention or treatment. In the emerging prophylactic pipeline, four therapies, i.e., V160, mRNA-1647, HB-101, Triplex are expected to launch, and one, i.e., prevymis is already approved. Whereas, in the therapeutic pipeline, two candidates are there, i.e., Maribavir, and Viralym-M.

Cytomegalovirus Infections Treatment

The available therapeutics treatment options in Chemotherapy-Induced Peripheral Neuropathy Landscape aim to reduce the disease burden. Triplex is a first-in-class, best-in-class, universal (non-HLA-restricted) recombinant modified vaccinia ankara viral vector vaccine engineered to induce a robust and durable virus-specific T cell response to three immuno- dominant proteins linked to CMV complications in the transplant setting: UL83 (pp65), UL123 (IE1) and UL122 (IE2). The drug was developed in partnership with the National Cancer Institute by its lead investigator, Diamond, of City of Hope. In a phase 1 study, Triplex was found to be safe, well-tolerated and highly immunogenic when administered to healthy volunteers.

Cytomegalovirus Infections Pipeline Report

When the infection threatens life or eyesight, an antiviral drug (valganciclovir, ganciclovir, cidofovir, foscarnet, or a combination) may be given. These drugs may be given by mouth or by vein. When CMV Infections retinitis is very severe, the drugs may also be injected directly into the eye. These drugs have serious side effects, which increase the demand and need for more potential therapies.

Cytomegalovirus Infections Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Cytomegalovirus (CMV) Infection.    
• In the coming years, the Cytomegalovirus (CMV) Infection market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. 
• The companies and academics that are working to assess challenges and seek opportunities that could influence Cytomegalovirus (CMV) Infection R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Cytomegalovirus (CMV) Infection treatment market. Several potential therapies for Cytomegalovirus (CMV) Infection are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Cytomegalovirus (CMV) Infection market size in the coming years.  
• Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Cytomegalovirus (CMV) Infection) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities. 

Download free sample copy here- https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-pipeline-insight

Following is the TOC of Cytomegalovirus Infections report

1. Report Introduction

2. Cytomegalovirus (CMV) Infection 

3. Cytomegalovirus (CMV) Infection Current Treatment Patterns

4. Cytomegalovirus (CMV) Infection – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Cytomegalovirus (CMV) Infection Late Stage Products (Phase-III)

7. Cytomegalovirus (CMV) Infection Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Cytomegalovirus (CMV) Infection Discontinued Products

13. Cytomegalovirus (CMV) Infection Product Profiles

14. Cytomegalovirus (CMV) Infection Key Companies

15. Cytomegalovirus (CMV) Infection Key Products

16. Dormant and Discontinued Products

17. Cytomegalovirus (CMV) Infection Unmet Needs

18. Cytomegalovirus (CMV) Infection Future Perspectives

19. Cytomegalovirus (CMV) Infection Analyst Review  

20. Appendix

21. Report Methodology

What are the key questions of the report?

• What are the current options for Cytomegalovirus (CMV) Infection treatment?
• How many companies are developing therapies for the treatment of Cytomegalovirus (CMV) Infection? 
• What are the principal therapies developed by these companies in the industry?
• How many therapies are developed by each company for the treatment of Cytomegalovirus (CMV) Infection?
• How many Cytomegalovirus (CMV) Infection emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Cytomegalovirus (CMV) Infection?
• Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies? 
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Cytomegalovirus (CMV) Infection market? 
• Which are the dormant and discontinued products and the reasons for the same?
• What is the unmet need for current therapies for the treatment of Cytomegalovirus (CMV) Infection?  
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Cytomegalovirus (CMV) Infection therapies? 
• What are the clinical studies going on for Cytomegalovirus (CMV) Infection and their status?
• What are the results of the clinical studies and their safety and efficacy? 
• What are the key designations that have been granted for the emerging therapies for Cytomegalovirus (CMV) Infection? 
• How many patents are granted and pending for the emerging therapies for the treatment of Cytomegalovirus (CMV) Infection? 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: www.delveinsight.com/